Food and Drug Administration - August 10, 2011
On August 10, 2011, FDA approved Complera(TM), a fixed dose
combination (FDC) drug product containing
emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the
treatment of HIV. The recommended dose of Complera(TM) is one
tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily,
taken orally with a meal.